In this novel method for quantifying bethanidine in plasma, after a multi-step extraction of bethanidine and internal standard from 2.0 mL of plasma, the drugs are separated on a "microbore" C18 reversed-phase column and quantified by their ultraviolet absorbance at 210 nm. The isocratic chromatographic separation takes about 15 mm with use of an ion-pairing regent in the mobile phase (acetate buffer/acetonitnle, 9/1 by vol) and a flow rate of 0.25 mL/min. Sensitivity is increased relative to conventional columns, and solvent consumption is reduced by 90%. The standard curve is linear to at least 5 mg/L, and the detection limit is 0.02 mg/L. The within-run precision of the method is excellent (CV 4%) at a midrange concentration of 1.25 mgIL.
old drug for which there may be a new indication. Originally investigated as an antihypertensive drug in the 1960s (1), it never enjoyed widespread use. Other workers noted that bethanidine was effective in suppressing ventricular tachycaL-diaand fibrillation (2); however, because of adverse side effects (persistent orthostatic hypotension), further clinical studies were abandoned. After it was learned that certain tricyclic drugs given in doseswell below that for antidepressant efficacy were effective antagonists of bethanidine's hypotensive action (3), Bacaner and Benditt (4) proposed that bethanidine combined with a tricyclic may be an effective oral means of preventing ventricular fibrillation in nonhospitalized patients, a major cause of death. In their recent clinical trial, this approach was used on a series of 23 patients whose condition could not be controlled with any combination of other antiarrhythmic drugs: 18 patients (78%) had complete suppression of spontaneous or electrophysiological inducible tachyarrhythmias. After it was decided to expand these clinical studies, we began the work reported here, to develop a sensitive and specific assay for bethanidine in plasma by reversed-phase, "high-performance" liquid chromatography (HPLC).
Materials and Methods

Samples.
Blood drawn into green-stopper (heparin) Vacutamer Tubes (Becton Dickinson, Rutherford, NJ 07070) was centrifuged within 2 h of venipuncture and the plasma stored at -20 #{176}C until assay. Distilled water shaken in these tubes and then carried through the entire procedure gave no extraneous peaks in the chromatogram. Drug-supplemented plasma standards treated similarly and frozen for as long as two weeks were analyzed, with results quantitatively identical to those for freshly prepared plasma standards. We Departments of Pathology,' Biochemistry,2 and Internal Medicine,3University of Virginia Medical Center, Charlottesville,VA 22908.
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thus concluded that the sampling procedure had no adverse effect on the analysis. Chemicals. "Distilled in glass" acetonitrile and chloroform from Burdick and Jackson were purchased from Bodman Chemicals, Media, PA 19063; the distilled water used in all HPLC work was obtained with the "Milli-Q" purification system (Millipore Corp., Bedford, MA 01730). All remaining chemicals used in buffer preparation and the extraction were ACS reagent grade (Fisher Scientific, Fairlawn, NJ 07410).
Standards.
Bethanidine hemisulfate was a gift from the manufacturer (A. H. Robins, Richmond, VA 23220). The with the microbore column and the detector set at a wavelength of 210 nm with a range of 0.1 A full-scale. Quantification is based on peak-area ratios of bethanidine and the internal standard. From a plot of these peak-area ratios vs concentration for the series of plasma standards, determine the concentration in the patient's sample by simple interpolation.
Results
Figure 1 illustrates representative chromatograms from aqueous bethanidine standards, drug-free plasma extracts, and a plasma extract from a patient receiving bethanidine.
In more than 20 plasma specimens known to be bethanidine-free,we observed no extraneous peaks with retention times in the vicinity of bethanidine or the internal standard. Patients in our clinical study received protriptyline, a drug that prevents bethanidine-induced orthostatic hypotension.
All other antiarrythmic drugs were discontinued. Drug-free plasma supplemented with protriptyline (1 mg/L) also gave no interfering peaks when analyzed by the proposed method. Similar results were obtained for added diazepam, which is used to premedicate the patients before cardiac catheterization. The patients' tacharrhythmias are drug refractory; i.e., clinical response is poor with all drugs. Thus, the concomitant administration of bethanidine with other antiarrhythmic drugs or tricyclic antidepressants other than protriptyline is not likely in clinical practice and certainly not indicated in clinical research studies. To detect other drug interferences, we obtained blood samples before the loading dose of bethanidine and analyzed them both with and without added internal standard. In none of our patients' samples were peaks observed at the retention times of bethanidine or of the internal standard. A graph of the peak-height ratios of bethanidine to internal standard for bethanidine-supplemented plasma was linear between 0.7 and 5.0 mg/L and passed through the origin with a correlation coefficient of 0.9996. The slope of the line is reproducible from day-to-day with a mean value of 0.948 (SD 0.02, n = 8). Although this range is optimum for our studies, instrument sensitivity is sufficient (25 ng gives a signal-to-noise ratio of 10) to permit lower limits of detection simply by increasing initial sample and injection volumes.
Analytical recovery and precision.
The present extraction procedure provides excellent recovery from aqueous solutions, ranging from 98 to 105% (mean 99%, n = 5). The recovery of bethanidine from a plasma sample to which 1.25 mgJL had been added was 100 ± 5% (n = 8). Repeated injections of a single low-concentration extract of plasma (mean 0.19 mg/L) gave a CV of 2% for the precision of the instrument.
The precision of the entire chromatographic procedure was evaluated by analyzing eight plasma samples, each with a concentration of 1.25 mgfL. With this sample, representing a typical peak plasma concentration, we obtained a CV of 4%. Day-to-day precision was estimated by analyzing the variance of a bethanidine-supplemented plasma control. Aliquots of the controlwere stored at -70 #{176}C and analyzed on consecutive days along with freshly prepared plasma standards. A mean value (n = 17) of 0.94 mg/L was obtained with a CV of 6.4%.
Pharmacokinetic data. The doses of betharndine used in these studies are substantially higher than usually peescribed when indicated for hypertension, and little is known of the pharmacokinetic parameters. From our data on a few patients, the dose-response curve in Figure 2 appears typical, with the peak concentration in plasma occurring 60-90 mm after a 20 mg/kg (body wt.) oral loading dose, the drug half-life being about 4 h.
Discussion
A search of the literature revealed two existing methods for plasma bethanidine: a fluorometric assay (5) and a gaschromatographic separation with quantitation by flame ionization or multiple ion detection (6) . In the fluorometric assay, bethanidine is extracted from plasma into chloroform and the fluorescence is then determined by using a drugdye complex formed with eosin Y. This assay is not specific for bethanidine and an internal standard cannot be used. The multistep extraction requires uniform timing in a dimly lit room and use of scrupulously clean, foil-covered tubes, and the fluorescence decays rapidly (T = 2 mm) in the excitation light path. Our attempts to duplicate the sensitivity and reproducibility of the method reported in this paper were unsuccessful.
Initialgas-liquid chromatographic studies in our laboratory revealed that underivatized bethanidine does not chromatograph well, and that the trifluoroacetyl and pentafluoropropionyl derivatives formed multiple products, which decomposed on removal of the anhydride. The chromatographic method with multiple ion detection reported for the analysis of another guanido-containing drug, guanethidine (6), involves a multistep extraction, removal of the guanido group by alkaline hydrolysis, and trifluoroacetylation of the resulting primary amine. This method permits the use of an internal standard but was not applied to the analysis for bethanidine in plasma. Our study confirmed the earlier finding that the alkaline hydrolysis of bethanidi#{241}e to benzylamine is not complete even after 24 h at 110 #{176}C, and that there is extensive decomposition at higher temperature. For these reasons, we believe both of the existing assays are unsuitable for rout ne use.
The extraction procedure was based on an earlier assay for guanethidine (6) . To optimize the extraction at basic pH, we investigated several solvents, including hexane, ether, ethyl acetate, toluene, and chloroform. Chloroform gave the best overall analytical recovery and phase separation. The initial ether extraction at neutral pH causes negligible loss of the drug, yet results in cleaner chromatograms and decreases emulsion formation in subsequent extraction steps. The final evaporative step is widely used in clinical toxicology laboratories to concentrate an extract easily and quickly. The sample can be both concentrated and placed in the solvent that is most suitable for the chromatographic separation.
The absolute uncorrected recovery of bethanidine, added to plasma to give a final concentration of 1.25 mgfL, averaged 43% (35-48%). Variable amounts of the drug are lost at each step when the entire added volume of an organic extract cannot be recovered owing to emulsion formation, but the use of an internal standard in the plasma standards taken through the extraction procedure fullycompensates for this variability. The relative recovery is quantitative and the results are precise.
In theinitial development of the present method, we used a conventional 25 cm x 4.6 mm C18reversed-phase column. The sodium acetate mobile phase was optimized by varying the concentration of acetonitrile to best resolve bethanidine from rapidly eluting plasma contaminant peaks without an unduly long analysis time. The addition of an ion-suppression reagent, tetramethylammonium chloride, resulted in improved chromatography by reducing peak tailing. The internal standard, N-methylphenylethylamine, one of many compounds tested for suitability as an internal standard, was chosen because of similar extraction characteristics and chromatographic proximity to bethanidine under the described conditions. Although the wavelength selectedprovided the best sensitivity, the molar absorptivity was too low to provide the required sensitivity. Attempts to improve the sensitivity by using fluorescent detection of dansyl chloride (DNS) derivatives of bethanidine were unsuccessful because multiple peaks formed. Mono-and di-DNS-bethanidine derivatives were identified by collecting fractions corresponding to chromatographic peaks and obtaining positiveion chemical ionization mass spectra of samples from each fraction, introduced via a solid probe inlet. Additionally, we found that the eluted bethanidine was not easily oxidized or reduced, effectively ruling out the use of an electrochemical detector, which is quite sensitive and selective for some drugs.
Recent reports that demonstrated lower detection limits with the use of microbore (0. 5-2.0mm i.d.) chromatographic columns (7) led us to investigate their use for the present application. With no modifications of pumps, injector, or detector, we observed a fivefold increase in peak area and greatly decreased noise as compared with the same amount of compound injected onto a conventional column. The only changes required were the reduction of the flow rate to 0.25 mb/mm and reversing the flow through the spectrophotometric detector to bypass the heat exchanger, to reduce extra-column band broadening. This modification so dramatically improved sensitivity and precision that the present method was adopted for routine use.
We have found that, when in continuous use, the useful life of these analytical columns is about six months and their relatively low cost allows replacement after 500 plasma samples. Lot-to-lot variation in column packing may require adjustment of the proportion of the organic modifier in the mobile phase, to duplicate retention times between different columns.
The value of bethanidine as a clinically useful drug for antifibrillatory prophylaxis remains to be established. Toward that goal, clinical trials in several centers are currently in progress. We believe that a readily available in-house assay for plasma bethanidine will aid in comparing the results from the various institutions regarding therapeutic efficacy. Additionally, the assay may be simply modified to measure both new and existing guanido-containing drugs.
